News /
min read /
February 3, 2024

Evolving Our Leadership At Big Health


Twelve years ago, my experience of insomnia and the struggle to get any treatment other than medication inspired me to found Big Health. From day one, our motivation has been to help millions with similar challenges back to good mental health, through digital treatments as scalable and accessible as drugs.

It’s amazing to me how far we’ve come since then.  Our digital therapeutics are backed by more than 70 clinical publications, including 14 randomized control trials. More participants have taken part in high quality controlled studies for Sleepio, our treatment for insomnia, than for Ambien1. Ten million people globally have reimbursed access to our products, thanks to pioneering partnerships with leading healthcare organizations from CVS Health to the United Kingdom’s NHS. Just a couple of months ago, the globally-respected guideline body National Institute for Health and Care Excellence (NICE) approved Sleepio as a recommended first-line treatment for insomnia ahead of medication – a first for a digital therapeutic.

We are finally on the cusp of digital therapeutics becoming a core part of the everyday delivery of medicine, with Big Health at the forefront of that revolution. At this moment of outsized potential, it’s become clear to me that we need to evolve our leadership in order to take advantage of the opportunity ahead of us.

I am excited to announce I am moving into the role of President, to continue driving strategy, partnerships, and vision full-time, in a way that best contributes to our growth. At the invitation of myself, co-founder Colin Espie, and the Big Health Board, I’m pleased to say that Arun Gupta, our Executive Chairman, has agreed to elevate his role to Executive Chairman and Acting CEO of the company. Arun joined our Board 3 years ago, bringing immense experience scaling health and technology companies. We were unanimous in our belief that Arun stepping into the CEO role would allow us to harness this moment of opportunity with additional high powered leadership capacity. In service of good governance, the Board, Arun and I will continue evaluating candidates to ensure the very best leadership configuration for this next chapter.

Since the day Colin and I founded Big Health, the mission to help millions has remained our north star. With this new leadership configuration, I’ve never been more convinced of our collective ability to reach the next level of scale, to provide reimbursed access to hundreds of millions globally, and as a result help millions back to good mental health.

Sleepio is available as an adjunct to usual medical care for insomnia disorder for adults ages 18 and older, without FDA review under their COVID-19 policy. Users are directed to not make any changes to their prescribed medication or other type of medical treatment without seeking professional medical advice.

For media inquiries, please contact

During the COVID-19 public health emergency, Sleepio and Daylight are being made available as treatments for insomnia disorder and generalized anxiety disorder (GAD), respectively, without a prescription. Sleepio and Daylight have not been cleared by the U.S. Food and Drug Administration (FDA) for the treatment of insomnia disorder and GAD, respectively.

1. Qaseem, A., Kansagara, D., Forciea, M. A., Cooke, M., & Denberg, T. D. (2016). Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 165(2), 125-133.2. Riemann, D., Baglioni, C., Bassetti, C., Bjorvatn, B., Dolenc Groselj, L., Ellis, J. G., … & Spiegelhalder, K. (2017). European guideline for the diagnosis and treatment of insomnia. Journal of Sleep Research, 26(6), 675-700.3. Wilson, S., Anderson, K., Baldwin, D., Dijk, D. J., Espie, A., Espie, C., … & Sharpley, A. (2019). British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: an update. Journal of Psychopharmacology, 33(8), 923-947.4. King’s Technology Evaluation Centre. (2017, November 9). Overview: Health app: SLEEPIO for adults with poor Sleep: Advice. NICE. Espie, C. A., Kyle, S. D., Williams, C., Ong, J. C., Douglas, N. J., Hames, P., & Brown, J. S. (2012). A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via an automated media-rich web application. Sleep, 35(6), 769-781.6. Carl, J. R., Miller, C. B., Henry, A. L., Davis, M. L., Stott, R., Smits, J. A., … & Espie, C. A. (2020). Efficacy of digital cognitive behavioral therapy for moderate‐to‐severe symptoms of generalized anxiety disorder: A randomized controlled trial. Depression and Anxiety, 37(12), 1168-1178.

DOC-3046 Effective 11/2023